Insider Selling: VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells $45,908.30 in Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 2,749 shares of the business’s stock in a transaction dated Thursday, July 16th. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30. Following the transaction, the insider owned 3,549,961 shares in the company, valued at $59,284,348.70. This represents a 0.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.71, for a total transaction of $109,166.43.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Stock Up 1.1%

Shares of BBH stock traded up $2.26 during midday trading on Thursday, reaching $206.25. 3,431 shares of the stock were exchanged, compared to its average volume of 6,008. VanEck Biotech ETF has a 1 year low of $154.75 and a 1 year high of $212.54. The company’s 50 day moving average is $192.26 and its two-hundred day moving average is $191.76.

Institutional Investors Weigh In On VanEck Biotech ETF

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Empowered Funds LLC bought a new position in VanEck Biotech ETF in the fourth quarter worth $38,000. Flagship Harbor Advisors LLC bought a new stake in shares of VanEck Biotech ETF during the 4th quarter valued at $47,000. Allworth Financial LP boosted its holdings in shares of VanEck Biotech ETF by 255.0% during the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after buying an additional 306 shares in the last quarter. Fifth Third Bancorp purchased a new stake in shares of VanEck Biotech ETF in the 1st quarter worth about $127,000. Finally, Huntington National Bank purchased a new stake in shares of VanEck Biotech ETF in the 4th quarter worth about $132,000. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.